

July 27, 2009

Dear Sirs:

Name of company: ASKA Pharmaceutical Co., Ltd.

Name of representative: President, Representative Director Takashi Yamaguchi
(Code No.: 4514; the first section of the Tokyo Stock Exchange)

Contact information: Motohiro Kobayashi, Senior Manager, Legal Affairs & Public
Relations Dept.)

(Tel.: +81-3-5484-8366)

**Agreements Concluded for “SELTOUCH® Pap 70, 140”
Transdermal Absorption-type Analgesic and Anti-inflammatory Agent**

Wyeth K.K. (Headquarters: Shinagawa-ku, Tokyo, President & Representative Director Michael Goettler, “WKK”), ASKA Pharmaceutical Co., Ltd (Headquarters: Minato-ku, Tokyo, President, Representative Director Takashi Yamaguchi, “ASKA”) and Takeda Pharmaceutical Company Limited (Headquarters: Chuo-ku, Osaka, President & CEO Yasuchika Hasegawa, “Takeda”) today announced changes to the Japanese distribution, sales and promotion for WKK’s transdermal absorption-type analgesic and anti-inflammatory agent, “SELTOUCH® Pap 70, 140” (“SELTOUCH”). WKK and ASKA signed an agreement in which the sales right for SELTOUCH is granted to ASKA. ASKA and Takeda also signed an agreement in which the sales and promotion of SELTOUCH are entrusted to Takeda.

Under these agreements, Takeda will assume promotion of SELTOUCH, starting October of this year, while continuing the sales to wholesalers.

WKK has been focusing on key strategic products in the areas of rheumatoid arthritis, oncology and hematology, and vaccines, and along with this strategy the company has given consideration to which company to entrust sales and promotion of SELTOUCH to, and has agreed to grant the sales right for SELTOUCH to ASKA. Through this agreement, it becomes possible for WKK to strengthen activities for its key strategic products.

Meanwhile, since promotional activities of ASKA are limited in the orthopedic surgery area, in which SELTOUCH is mainly prescribed, it has decided to entrust promotion to Takeda, focusing on the physical distribution of SELTOUCH to Takeda.

Takeda has a solid foundation in the area of orthopedic surgery through the promotion of the therapeutic agents “Enbrel®” for rheumatoid arthritis which it co-promotes with WKK, and “Benet®” for osteoporosis. Takeda will further increase its presence in this area through the promotion of SELTOUCH.

For inquiries:

Wyeth K.K., Corporate Affairs

TEL 03-6420-6907

ASKA Pharmaceutical Co. Ltd., Legal Affairs & Public Relations Dept.

TEL 03-5484-8366

Takeda Pharmaceutical Co. Ltd., Corporate Communications Dept.

TEL 03-3278-2037

[Reference]

About SELTOUCH

SELTOUCH is an adhesive skin poultice jointly developed by WKK and Teikoku Seiyaku, which first sold in 1993. It is a non-steroidal analgesic anti-inflammatory drug containing Felbinac, and is absorbed transdermally. The active ingredients infiltrate into the site of inflammation through the area of the skin to which the patch is attached, and rapidly exert their analgesic and anti-inflammatory effects. The product is characterized by its non-scented properties. Two varieties of the product are currently available in the market—SELTOUCH Pap 70 (10 x 14cm), and the large-sized format SELTOUCH Pap 140 (20 x 14cm).

Sales for fiscal 2008: 11,300 million yen

<About WKK>

Wyeth K.K. is engaged in a full range of pharmaceutical business activities including developing, importing and marketing pharmaceutical products with the aim of becoming a leading company in the pharmaceutical industry in Japan. Our corporate vision is *Leading the Way to a Healthier World*. We strive to achieve this vision by bringing to the world pharmaceutical and health-care products that improve peoples' lives and deliver outstanding value to our customers. Headquartered in Tokyo, Wyeth K.K. has approximately 1,000 employees.

Visit <http://www.wyeth.jp> for more details.

<About ASKA>

ASKA Pharmaceutical Co., Ltd. aims to contribute extensively to society through the development and provision of revolutionary and innovative pharmaceutical products, establishing itself as a research and development oriented company specializing in specific fields, and focusing its management resources on the development of new products in these fields, based on the companies corporate philosophy to “Contribute toward improvement of people’s health and progress in medicine through development of innovative pharmaceutical products”. The company has 1,042 staff under its employment, and its products have made forays into the areas of internal medicine (gastroenterological, cardiovascular, and thyroid glandular), urology, otolaryngology, as well as obstetrics and gynecology.

Visit <http://www.ASKA-pharma.co.jp/> for more details.

<About Takeda>

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Takeda is enhancing its R&D pipeline by concentrating its management resources in the following selected core therapeutic areas: “lifestyle-related diseases,” “oncology and urological diseases (including gynecology),” “central nervous system diseases (including bone and joint disorders),” and “gastroenterological diseases.”

For more information, please visit <http://www.takeda.com>